-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $249

Benzinga·07/31/2026 20:54:52
语音播报
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $246 to $249.